-transparent.png){kind=logo}
Seventeen ambulant outpatients with familial Type IIa or Type IIb hyperlipoproteinaemia were treated with Cynarin, the 1,5-dicaffeyl ester of quinic acid, the constituent of the artichoke (Cynara scolymus). The dose tested was 250 mg and 750 mg daily. The mean serum cholesterol and triglyceride concentrations were not significantly changed within 3 months. Cynarin, administered per os, has no hypolipidaemic effect in familial Type II hyperlipoproteinaemia.
Related Publications
H Heckers, and
K Dittmar, and
F W Schmahl, and
K Huth
January 1973,
Lancet (London, England),
H Heckers, and
K Dittmar, and
F W Schmahl, and
K Huth
May 1973,
The Medical journal of Australia,
H Heckers, and
K Dittmar, and
F W Schmahl, and
K Huth
June 1981,
Lancet (London, England),
H Heckers, and
K Dittmar, and
F W Schmahl, and
K Huth
March 1973,
Clinics in endocrinology and metabolism,
H Heckers, and
K Dittmar, and
F W Schmahl, and
K Huth
June 1973,
Singapore medical journal,
H Heckers, and
K Dittmar, and
F W Schmahl, and
K Huth
January 1982,
Annales de medecine interne,
H Heckers, and
K Dittmar, and
F W Schmahl, and
K Huth
January 2013,
The Netherlands journal of medicine,
H Heckers, and
K Dittmar, and
F W Schmahl, and
K Huth
May 1982,
Lancet (London, England),
H Heckers, and
K Dittmar, and
F W Schmahl, and
K Huth
January 1990,
European journal of clinical pharmacology,
H Heckers, and
K Dittmar, and
F W Schmahl, and
K Huth
June 1977,
British journal of clinical pharmacology,
